BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24986238)

  • 1. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
    Alakus H; Bollschweiler E; Hölscher AH; Warnecke-Eberz U; Frazer KA; Harismendy O; Lowy AM; Mönig SP; Eberz PM; Maus M; Drebber U; Siffert W; Metzger R
    Ann Surg Oncol; 2014 Dec; 21(13):4375-82. PubMed ID: 24986238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GNAS1 T393C polymorphism predicts survival in patients with advanced squamous cell carcinoma of the larynx.
    Lehnerdt GF; Franz P; Winterhoff S; Bankfalvi A; Grehl S; Lang S; Schmid KW; Siffert W; Jahnke K; Frey UH
    Laryngoscope; 2008 Dec; 118(12):2172-6. PubMed ID: 19029852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.
    Lehnerdt GF; Franz P; Zaqoul A; Schmitz KJ; Grehl S; Lang S; Schmid KW; Siffert W; Jahnke K; Frey UH
    Clin Cancer Res; 2008 Mar; 14(6):1753-8. PubMed ID: 18347176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
    Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
    Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
    Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
    Markar SR; Bodnar A; Rosales J; Song G; Low DE
    Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
    Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
    World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.
    Griffin JM; Reed CE; Denlinger CE
    Ann Thorac Surg; 2012 Jun; 93(6):1855-9; discussion 1860. PubMed ID: 22516835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
    Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
    Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
    Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
    Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer.
    Vashist YK; Kutup A; Musici S; Yekebas EF; Mina S; Uzunoglu G; Zehler O; Koenig A; Cataldegirmen G; Bockhorn M; Effenberger K; Kalinin V; Pantel K; Izbicki JR
    Cell Oncol (Dordr); 2011 Aug; 34(4):281-8. PubMed ID: 21340746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.